Xylem Looking To Supercharge Growth With Targeted Acquisitions—Is The Vacom Deal Just The Start?

Xylem Inc. closed the first quarter of 2025 with a performance that surpassed expectations and reaffirmed their guidance for the year. The company reported a robust revenue increase across all segments, contributing to a 120 basis point rise in EBITDA margin and a double-digit growth in earnings per share (EPS), which hit $1.03, outpacing the guidance midpoint by $0.08. Maintaining a backlog of $5.1 billion, Xylem showcased resilience in demand with a book-to-bill ratio exceeding one, although orders slightly dipped due to challenging comparisons in key segments.